You are here
Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Until recently the management of metastatic prostate cancer was straightforward with primary and secondary androgen deprivation followed by docetaxel-based chemotherapy once castration resistant disease had developed. This quite simple approach has changed dramatically over the last 2-3 years. Abiraterone acetate, Enzalutamide, and Radium-223 represent new active drugs which have been shown to improve survival in the pre- and in the post docetaxel era. Current clinical trials even evaluate the role of Enzalutamide and Abiraterone acetate as primary hormonal therapeutic approach. Sipuleucel-T, tasquinimod, and ipilimumab have been shown to exert some immunomodulatory effects with a significant therapeutic response in metastatic castration resistant prostate cancer. Innovative cytotoxic drugs such as cabazitaxel and molecular targeted approaches provide novel sequencing options to improve the treatment for patients with metastatic castration resistant prostate cancer.
The treating urologists and oncologists are often overwhelmed by the many new developing aspects in diagnosis and treatment of castration resistant prostate cancer and might be overstrained to adequately assess the clinical relevance of the new developments.
With the new tool of the Prostate Cancer Resource Centre, it is our goal to offer an informative platform to the interested uro-oncologist with regard to the latest developments in the management of castration resistant prostate cancer. We will inform the community about the most recent publications and clinical trials, and we will have international specialists referring their appraisal and experience with the new substances.
With kind regards,
Kurt Miller and Axel S. Merseburger